Michael von Bergwelt-Baildon

42PUBLICATIONS
310CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Oct 06, 2026
A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.

|Sep 21, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.

|Aug 24, 2026
TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

|Jun 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

|Jun 01, 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

|Dec 04, 2025
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.

Monika Sponheimer, Kieron White, Michelle Ulrich

Pageof 7

Frequent Collaborators

13 joint publications

Veit L Buecklein

10 joint publications

Kai Rejeski

7 joint publications

Karsten Spiekermann

6 joint publications

Michael D Jain